SCHEMBL5358233

SCHEMBL5358233

O=C1Nc2ccc(I)cc2C1=Cc1cccs1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 1/20 0.62
NTRK1 P04629 2/20 0.56
MAPT P10636 5/20 0.53
RAF1 P04049 3/20 0.53
HPGD P15428 3/20 0.53
KMT2A Q03164 3/20 0.53
HTT P42858 3/20 0.53
APP P05067 2/20 0.53
MAP1LC3B Q9GZQ8 2/20 0.53
EGFR P00533 2/20 0.53
MEN1 O00255 2/20 0.53
LMNA P02545 2/20 0.53
TP53 P04637 2/20 0.53
POLB P06746 2/20 0.53
MAPK1 P28482 2/20 0.53
ARAF P10398 1/20 0.53
PIM1 P11309 1/20 0.53
BRAF P15056 1/20 0.53
CSNK2A1 P68400 1/20 0.53
PIM3 Q86V86 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5999570 0.84 PDPK1 (0.65) PDPK1NTRK1PAK4RETTGM2
SCHEMBL29638268 0.84 NTRK1 (0.65) PDPK1NTRK1MAPTKMT2AEGFR
SCHEMBL18499300 0.84 PDPK1 (0.62) PDPK1NTRK1HPGDKMT2AHTT
SCHEMBL3747231 0.84 NTRK1 (0.65) PDPK1NTRK1MAPTKMT2AEGFR
SCHEMBL3749915 0.84 PDPK1 (0.62) PDPK1NTRK1MAPTKMT2AMAP1LC3B
SCHEMBL24967152 0.84 PDPK1 (0.65) PDPK1NTRK1MAPTHPGDKMT2A
SCHEMBL5999571 0.84 PDPK1 (0.65) PDPK1NTRK1PAK4RETTGM2
SCHEMBL3749912 0.84 PDPK1 (0.62) PDPK1NTRK1MAPTKMT2AMAP1LC3B
SCHEMBL3747230 0.84 NTRK1 (0.65) PDPK1NTRK1MAPTKMT2AEGFR
SCHEMBL3754999 0.81 KDR (0.69) PDPK1NTRK1MAPTHPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK PDPK1 31/4885NTRK1 223/4885MAPT 3048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.